Analyst Price Targets — ANAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2026 2:51 pm | — | Leerink Partners | $90.00 | $62.65 | TheFly | AnaptysBio price target raised to $90 from $85 at Leerink |
| May 13, 2026 11:33 am | — | UBS | $76.00 | $65.58 | TheFly | AnaptysBio price target raised to $76 from $60 at UBS |
| May 13, 2026 8:56 am | — | Barclays | $75.00 | $65.58 | TheFly | AnaptysBio price target raised to $75 from $63 at Barclays |
| April 28, 2026 10:21 am | — | Leerink Partners | $85.00 | $66.59 | TheFly | AnaptysBio price target raised to $85 from $66 at Leerink |
| April 21, 2026 12:28 pm | — | UBS | $60.00 | $54.23 | TheFly | AnaptysBio price target lowered to $60 from $90 at UBS |
| March 6, 2026 2:07 pm | John Lee | Truist Financial | $50.00 | $56.29 | StreetInsider | AnaptysBio (ANAB) PT Raised to $50 at Truist Securities on improved outlook for Jemperli |
| March 5, 2026 11:54 am | Alex Thompson | Stifel Nicolaus | $85.00 | $57.36 | StreetInsider | AnaptysBio (ANAB) PT Raised to $85 at Stifel After Q4 Update |
| March 4, 2026 11:41 am | Emily Bodnar | H.C. Wainwright | $66.00 | $58.04 | StreetInsider | AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright |
| January 7, 2026 5:39 am | Michael Yee | UBS | $70.00 | $43.91 | StreetInsider | UBS Assumes AnaptysBio (ANAB) at Buy |
| December 18, 2025 1:24 pm | — | Guggenheim | $140.00 | $46.23 | TheFly | AnaptysBio price target raised to $140 from $100 at Guggenheim |
Latest News for ANAB
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANAB.
U.S. House Trading
No House trades found for ANAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.